Top Markets
#1 NEW X CEO IS BACK NEW X CEO IS BACK +190,916.81%
#2 Beta Finance Beta Finance +8,977.34%
#3 Velas Velas +461.19%
#4 Tribe Tribe +73.83%
#5 Orochi Network Orochi Network +51.29%
#6 Chainbase Chainbase +40.86%
#7 BabyBoomToken BabyBoomToken +34.51%
#8 Freysa AI Freysa AI +33.79%
#9 Block Street Block Street +28.93%
#10 Chrema Coin Chrema Coin +27.48%
Coin of the day
NEW X CEO IS BACK NEW X CEO IS BACK
설정
언어
한국어
통화
USD
테마
Nuformix plc Nuformix plc

Nuformix plc

NFX
주식 순위 #20651
Nuformix plc operates in the field of pharmaceutical development for treating... Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
주가
$0.00244926
시가총액
$51.67K
변동 (1일)
5.88%
변동 (1년)
110.15%
국가
GB
거래 Nuformix plc (NFX)

카테고리

Healthcare
Nuformix plc (NFX)의 배당 이력
Nuformix plc (주식 심볼: NFX)은 총 0회의 배당금을 지급했습니다.
모든 배당금의 합계 (주식 분할 반영): 0.00
배당 수익률 (TTM): 0
Nuformix plc (NFX)의 2026부터 2026까지 배당 지급 내역
연간 배당 지급
연도 배당금 (주식 분할 조정됨) 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
모든 배당 지급 목록
연도 배당금 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 배당 지급
회사 배당 지급 횟수 국가
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
52.00%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
5.00%
US
UCB SA UCB SA
UCB SA
UCB.BR
29.00%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU